Acute coronary syndrome market to grow to over $12 billion by 2022
pharmafile | August 15, 2016 | News story | Research and Development, Sales and Marketing | GlobalData, acute coronary syndrome
The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 with a compound annual growth rate of 4.6%, research and consulting firm GlobalData predicts.
According to the company, this growth will be driven by the launch of several new lipid targeting therapies for statin intolerant patients and those who require additional lowering of low-density lipoprotein C (LDL-C) in combination to statin therapy; specifically, the launches of the first proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors), Repatha (evolocumab) and Praluent (alirocumab) by 2016 and Esperion’s ETC-1002 by 2021.
A novel lipid-lowering drug, ETC-1002 has produced strong results in its Phase IIb study and is initiating Phase III trials in 2016. As an oral, once-daily treatment, GlobalData predicts Esperion may be able to seize the majority of patient share from the statin-intolerant patient population.
“At present, a large proportion of patients with clinical atherosclerotic cardiovascular disease cannot reach guideline recommended levels of LDL-C with the standard of care therapies, which leads to recurrent ACS events,” explained Michela J. McMullan, GlobalData’s analyst covering cardiovascular and metabolic disorders. “However, the revolutionary PCSK9 inhibitors Repatha and Praluent have both truly demonstrated their efficacy in lowering LDL-C in their pivotal Phase III trials, as 57% and 58% reductions in LDL-C from baseline compared to placebo were observed for evolocumab and alirocumab, respectively.”
“Generally speaking, the ACS market is a highly lucrative area for pharmaceutical companies to invest in drug development,” McMullan continued. “Historically, Merck was the leading innovator in this space, boasting a multitude of therapies to combat atherosclerosis, such as the first-in-class statin Mevacor (lovastatin), as well as Zocor (simvastatin) and the cholesterol absorption inhibitor Zetia (ezetimibe).
“However, all of these drugs will lose patent exclusivity within the first half of the forecast period, so it is unlikely that Merck will maintain a competitive position during the forecast period. Amgen and Sanofi/Regeneron, developers of the newly launched PCSK9 inhibitors Repatha (evolocumab) and Praluent (alirocumab), respectively, are now seen as the leading innovators in the lipid–lowering arena.”
Matt Fellows
Related Content
Ovarian cancer market set to smash $6.7 billion by 2025
New research from GlobalData has forecast that the worldwide market for ovarian cancer is set …
Healthcare industry could take up to five years to stabilise after no-deal Brexit
The healthcare industry could take up to five years to stabilise in the event of …
Heart failure market to quadruple in ten years to $16 billion
New research from intelligence firm GlobalData has indicated that the market for heart failure drugs …
